Skip to main content

Table 3 Before-after comparison of the outcome measures in patient receiving pregabalin ± agomelatine

From: The effectiveness of pregabalin with or without agomelatine in the treatment of chronic low back pain: a double-blind, placebo-controlled, randomized clinical trial

Outcome of interest

Pregabalin ± Agomelatine

(n = 23)

F

P-Value

BPI

• Week 0

• Week 4

• Week 8

5.72 ± 1.25

4.21 ± 0.8

3.23 ± 0.97

67.63

< 0.001

RMDQ

• Week 0

• Week 4

• Week 8

10.7 ± 4.94

7.65 ± 4.16

5.87 ± 3.82

43.03

< 0.001

SF-36

• Week 0

• Week 4

• Week 8

46.78 ± 13.65

56.43 ± 9.47

62.61 ± 9.99

49.55

< 0.001

HADS

• Week 0

• Week 4

• Week 8

14.52 ± 6.02

11.61 ± 4.57

9.74 ± 5.24

14.1

< 0.001

GHQ-28

• Week 0

• Week 4

• Week 8

28.52 ± 8.58

21 ± 7.53

15.43 ± 5.8

90.36

< 0.001

  1. BPI: Brief Pain Inventory; RMDQ: Roland-Morris Disability Questionnaire; SF-36: 36-Item Short Form Survey; HADS: Hospital Anxiety and Depression Scale; GHQ-28: General Health Questionnaire – 28
  2. Data are presented with mean ± SD and analyzed by repeated measure ANOVA and Greenhouse-Geisser correction. A P < 0.05 is considered significant